InsiderSource
BBIO

BridgeBio Pharma, Inc.

SEC CIK 1743881
$66.80 −11.2% · 90 days
90-day buys
$0
0 open-market
90-day sells
$19.38M
41 open-market
Net insider flow
−$19.38M
Net selling
Filings shown
119
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at BBIO have sold a net $19.38M of stock (0 open-market buys vs 41 sells).

Largest recent trade: Homcy Charles J sold $8.79M of BBIO, trimming their stake 16%.

Most active filer: Kumar Neil, with 80 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for BBIO, newest first
View on SEC EDGAR ↗
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed May 11, 2026 ΔOwn −0.1%

Kumar Neil sold $341.8K of BBIO.

−$341.8K
5,076 sh @ $67
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed May 11, 2026 ΔOwn −1.9%

Kumar Neil sold $757.1K of BBIO, trimming their stake 2%.

−$757.1K
11,217 sh @ $67
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed May 11, 2026 ΔOwn −1.4%

Kumar Neil sold $569.8K of BBIO, trimming their stake 1%.

−$569.8K
8,333 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed May 11, 2026 ΔOwn −0.1%

Kumar Neil sold $31.1K of BBIO.

−$31.1K
450 sh @ $69
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed May 11, 2026 ΔOwn −0.3%

Kumar Neil sold $757.1K of BBIO.

−$757.1K
11,217 sh @ $67
Advertisement
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed May 11, 2026 ΔOwn −0.2%

Kumar Neil sold $569.9K of BBIO.

−$569.9K
8,334 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed May 11, 2026

Kumar Neil sold $31K of BBIO.

−$31K
449 sh @ $69
BBIO
BridgeBio Pharma, Inc.
Sell Apuli Maricel · Chief Accounting Officer · Open-market sale · filed May 4, 2026 ΔOwn −1.5%

Apuli Maricel sold $143.2K of BBIO, trimming their stake 1%.

−$143.2K
2,000 sh @ $72
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Apr 13, 2026 ΔOwn −3.2%

Kumar Neil sold $1.49M of BBIO, trimming their stake 3%.

−$1.49M
20,000 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Apr 13, 2026 ΔOwn −0.5%

Kumar Neil sold $1.49M of BBIO.

−$1.49M
20,000 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Apr 13, 2026 ΔOwn −1.1%

Kumar Neil sold $530.2K of BBIO, trimming their stake 1%.

−$530.2K
7,200 sh @ $74
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Apr 13, 2026 ΔOwn −0.8%

Kumar Neil sold $395.4K of BBIO, trimming their stake 1%.

−$395.4K
5,300 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Apr 13, 2026 ΔOwn −1.2%

Kumar Neil sold $566.7K of BBIO, trimming their stake 1%.

−$566.7K
7,500 sh @ $76
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Apr 13, 2026 ΔOwn −0.2%

Kumar Neil sold $520.8K of BBIO.

−$520.8K
7,072 sh @ $74
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Apr 13, 2026 ΔOwn −0.1%

Kumar Neil sold $382.4K of BBIO.

−$382.4K
5,128 sh @ $75
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Apr 13, 2026 ΔOwn −0.2%

Kumar Neil sold $589.1K of BBIO.

−$589.1K
7,800 sh @ $76
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Mar 16, 2026 ΔOwn −1.5%

Kumar Neil sold $662.4K of BBIO, trimming their stake 1%.

−$662.4K
9,690 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Mar 16, 2026 ΔOwn −1.6%

Kumar Neil sold $713.4K of BBIO, trimming their stake 2%.

−$713.4K
10,310 sh @ $69
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Mar 16, 2026 ΔOwn −0.2%

Kumar Neil sold $700.3K of BBIO.

−$700.3K
10,241 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Mar 16, 2026 ΔOwn −0.2%

Kumar Neil sold $675.6K of BBIO.

−$675.6K
9,759 sh @ $69
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Mar 16, 2026 ΔOwn −2.1%

Kumar Neil sold $981.8K of BBIO, trimming their stake 2%.

−$981.8K
14,337 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Mar 16, 2026 ΔOwn −0.8%

Kumar Neil sold $371.8K of BBIO, trimming their stake 1%.

−$371.8K
5,363 sh @ $69
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Mar 16, 2026

Kumar Neil sold $21K of BBIO.

−$21K
300 sh @ $70
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Mar 16, 2026 ΔOwn −0.3%

Kumar Neil sold $950.7K of BBIO.

−$950.7K
13,885 sh @ $68
BBIO
BridgeBio Pharma, Inc.
Sell Kumar Neil · Director, Chief Executive Officer · Open-market sale · filed Mar 16, 2026 ΔOwn −0.1%

Kumar Neil sold $402.9K of BBIO.

−$402.9K
5,815 sh @ $69
BBIO
BridgeBio Pharma, Inc.
Sell Valantine Hannah · Director · Open-market sale · filed Mar 12, 2026 ΔOwn −54%

Valantine Hannah sold $624.3K of BBIO, trimming their stake 54%.

−$624.3K
8,671 sh @ $72
Advertisement

About BBIO insider activity

This page tracks every recent Form 4 filed for BridgeBio Pharma, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is BBIO insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for BridgeBio Pharma, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.